236 related articles for article (PubMed ID: 19563061)
21. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.
Brown C; Ling F; Wan J
J Reprod Med; 2002 Jan; 47(1):14-22. PubMed ID: 11838304
[TBL] [Abstract][Full Text] [Related]
22. Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 μg compared with a 21/7 regimen of desogestrel 150 μg/ethinylestradiol 20 μg: a pooled analysis.
Anttila L; Neunteufel W; Petraglia F; Marr J; Kunz M
Clin Drug Investig; 2011; 31(8):519-525. PubMed ID: 21721590
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene.
Halbe HW; de Melo NR; Bahamondes L; Petracco A; Lemgruber M; de Andrade RP; da Cunha DC; Guazelli CA; Baracat EC
Eur J Contracept Reprod Health Care; 1998 Sep; 3(3):113-20. PubMed ID: 9853201
[TBL] [Abstract][Full Text] [Related]
24. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives.
Seeger JD; Loughlin J; Eng PM; Clifford CR; Cutone J; Walker AM
Obstet Gynecol; 2007 Sep; 110(3):587-93. PubMed ID: 17766604
[TBL] [Abstract][Full Text] [Related]
25. Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol acetate and 17β-estradiol: a randomized controlled trial.
Westhoff C; Kaunitz AM; Korver T; Sommer W; Bahamondes L; Darney P; Verhoeven C
Obstet Gynecol; 2012 May; 119(5):989-99. PubMed ID: 22525910
[TBL] [Abstract][Full Text] [Related]
26. Clinical evaluation of a monophasic ethinylestradiol/desogestrel-containing oral contraceptive.
Bilotta P; Favilli S
Arzneimittelforschung; 1988 Jul; 38(7):932-4. PubMed ID: 2974702
[TBL] [Abstract][Full Text] [Related]
27. Cycle control and side effects of a new combiphasic oral contraceptive regimen.
Dieben TO; op ten Berg MT; Coelingh Bennink HJ
Arzneimittelforschung; 1994 Jul; 44(7):877-9. PubMed ID: 7945527
[TBL] [Abstract][Full Text] [Related]
28. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life.
Borenstein J; Yu HT; Wade S; Chiou CF; Rapkin A
J Reprod Med; 2003 Feb; 48(2):79-85. PubMed ID: 12621790
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in a 24+4-day regimen in China].
Caiyan W; Wen D; Qinping L; Huan S; Ziyan H; Liangdan T; Zheng'ai X; Yufeng L; Shulan Z; Baihua D; Xiaoyan X; Mulan R; Xiaomao L; Youdi X; Zhisong M; Meiqing X; Hongyu W; Zirong H
Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):355-9. PubMed ID: 25030732
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of a new oral contraceptive containing drospirenone.
Shulman LP
J Reprod Med; 2002 Nov; 47(11 Suppl):981-4. PubMed ID: 12497672
[TBL] [Abstract][Full Text] [Related]
31. [Clinical evaluation of desogestrel, the first new-generation progestagen, practil 21, on 13,290 women and 74,967 cycles].
Bilotta P; Favilli S
Minerva Ginecol; 1987 Dec; 39(12):855-69. PubMed ID: 3329705
[No Abstract] [Full Text] [Related]
32. [A clinical trial of a monophasic contraceptive preparation containing ethinyl estradiol and desogestrel].
Bilotta P; Favilli S
Akush Ginekol (Mosk); 1992; (8-12):40-3. PubMed ID: 1292360
[TBL] [Abstract][Full Text] [Related]
33. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
[TBL] [Abstract][Full Text] [Related]
34. Drospirenone: high risk of venous thrombosis.
Prescrire Int; 2011 Feb; 20(113):43-5. PubMed ID: 21488592
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone.
Bachmann G; Sulak PJ; Sampson-Landers C; Benda N; Marr J
Contraception; 2004 Sep; 70(3):191-8. PubMed ID: 15325887
[TBL] [Abstract][Full Text] [Related]
36. Multicentre study with a new biphasic oral contraceptive containing ethinylestradiol and desogestrel. Report on efficacy, cycle control and adverse experiences with special emphasis on blood pressure and weight.
Dieben TO; van Beek A; Coelingh Bennink HJ
Arzneimittelforschung; 1991 Sep; 41(9):996-8. PubMed ID: 1839126
[TBL] [Abstract][Full Text] [Related]
37. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.
Fenton C; Wellington K; Moen MD; Robinson DM
Drugs; 2007; 67(12):1749-65. PubMed ID: 17683173
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters.
Douxfils J; Klipping C; Duijkers I; Kinet V; Mawet M; Maillard C; Jost M; Rosing J; Foidart JM
Contraception; 2020 Dec; 102(6):396-402. PubMed ID: 32956694
[TBL] [Abstract][Full Text] [Related]
39. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
Tans G; Curvers J; Middeldorp S; Thomassen MC; Meijers JC; Prins MH; Bouma BN; Büller HR; Rosing J
Thromb Haemost; 2000 Jul; 84(1):15-21. PubMed ID: 10928463
[TBL] [Abstract][Full Text] [Related]
40. Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: results of three multicentre trials.
Bitzer J; Paoletti AM
Clin Drug Investig; 2009; 29(2):73-8. PubMed ID: 19133702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]